✦ LIBER ✦

Mitomycin C and menadione for the treatment of lung cancer: a phase II trial

✍ Scribed by Merry Tetef; Kim Margolin; Chul Ahn; Steven Akman; Warren Chow; Lucille Leong; Robert J. Morgan; James Raschko; George Somlo; James H. Doroshow

Publisher: Springer US
Year: 1995
Tongue: English
Weight: 509 KB
Volume: 13
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00872865

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of irinotecan, cisplatin

Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer

✍ Dean A. Fennell; Jeremy P.C. Steele; Jonathan Shamash; Sarah E. Slater; Michael 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 87 KB 👁 1 views

## Abstract There is no standard therapy for relapsed small cell lung cancer (rSCLC). We evaluated the efficacy and toxicity of a new triplet consisting of irinotecan (100 mg/m^2^ Days 1 and 15 q28), cisplatin (40 mg/m^2^ Days 1 and 15 q28) and mitomycin (6 mg/m^2^ d1 q28) administered to a maximum

Mitomycin C, vinblastine, and carboplati

Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer: A phase II trial

✍ Adriano Paccagnella; Adolfo Favaretto; Francesco Oniga; Giuliana Festi; Stefano 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 702 KB

## BACKGROUND. The mitomycin C, vinblastine, and cisplatin (MVP) combination is one of the most frequently used in the palliative setting, but it produces considerable toxicity. Carboplatin and cisplatin have different patterns of toxicity. The goal of this study was to evaluate a combination simi

Phase II trial of streptozotocin, mitomy

Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer

✍ R. Glen Wiggans; Paul V. Woolley III; John S. Macdonald; Tarilyn Smythe; Winston 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 440 KB 👁 2 views

A phase III trial of mitomycin C alone v

A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma

✍ Michael H. Veeder; James R. Jett; John Q. Su; James A. Mailliard; John F. Foley; 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 628 KB

Phase II trial of edatrexate in small ce

Phase II trial of edatrexate in small cell lung cancer

✍ Martin Wiesenfeld; James R. Jett; John Q. Su; Theodore A. Braich; Carl G. Kardin 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 2 views

Combined cisplatin, doxorubicin, and mit

Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma : A Phase II FONICAP trial

✍ Maria Cristina Pennucci; Andrea Ardizzoni; Paolo Pronzato; Marina Fioretti; Clau 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 2 views

and cisplatin (P) yielded an objective response rate of 25% and a subjective response rate of 50% in patients with mesothelioma. In human mesothelioma cell